🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

Recruitingn/aAges 18 Years - anyAllNational Institute of Allergy and Infectious Dise…
NCT00867269 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background: * Idiopathic CD4+ lymphocytopenia (ICL) is a condition in which there is a decreased level of CD4+ lymphocytes (a type of white blood cell), which can lead to opportunistic infections or autoimmune disorders and diseases. Objectives: * To characterize the natural history with regard to CD4+ T cell count and onset of infection, malignancy, and autoimmunity. * To describe the immunological status of patients affected by ICL while providing the best possible standard therapy to eradicate opportunistic infections. * To establish the timeline of CD4 lymphocytopenia, with particular focus on defining subgroups of patients according to the decline, stabilization, or rise of CD4+ T cell counts over time. * To characterize the opportunistic infections that occur in ICL patients at microbiologic and molecular levels. * To characterize the immunophenotype and possible genetic immunod

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
* ICL PARTICPANT INCLUSION CRITERIA: To be eligible for this study, patients must satisfy all of the following inclusion criteria: 1. Age greater than or equal to 18 years 2. Absolute CD4 count \< 300 cells/microL or \< 20% of total T cells on at least two occasions at least 6 weeks apart 3. Ongoing care by a referring primary care physician 4. Willingness to allow storage of blood and tissue samples for future analysis ICL PARTICPANT EXCLUSION CRITERIA: Patients will be ineligible for this study if they satisfy any of the following criteria: 1. Known infection with HIV-1, HIV-2, or human T-cell lymphotropic viruses (HTLV-1 or HTLV-2) as demonstrated by enzyme-linked immunosorbent assay (ELISA) and western blot and/or viral load testing 2. Known underlying immunodeficiency syndrome other than ICL 3. Evidence of active malignancy 4. Receipt of medications, herbal substances, or biologic agents known to diminish the CD4+ count within 30 days of when the CD4+ lymphocytopenia was detected 5. Any condition that in the judgment of the investigators would place the subject at undue risk or compromise the results of the study. BLOOD RELATIVE INCLUSION CRITERIA: To be eligible for study participation as a blood relative, subjects must be greater than or equal to 18 years of age and be a blood relative of an individual who meets or has met the CDC criteria for ICL. HOUSEHOLD CONTACT INCLUSION CRITERIA: To be eligible for study participation as a household contact, subjects must be greater than or equal to18 years of age and live within the same household as an ICL subjects participating in this protocol. Blood relatives who are household contacts are eligible to participate.
💊

What it tests

  • Not listed
📍

Where

1 site
National Institutes of Health Clinical Center
Bethesda, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy